Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress ...Middle East

SAN FRANCISCO, Sept. 7, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced data presentations from two Phase 1b, proof-of-concept studies of rezpegaldesleukin (also known as LY3471851 or NKTR-358) in patients with atopic dermatitis (AD) and plaque psoriasis at the...

Hence then, the article about nektar therapeutics presents data for rezpegaldesleukin ly3471851 in patients with atopic dermatitis and psoriasis from two separate clinical studies at 2022 european academy of dermatology eadv congress was published today ( Wednesday 07/09/2022 - 08:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress )

Also on site :

• Gwyneth Paltrow’s surprisingly racy Oscars 2026 dress is slit all the way up the sides
• Conan O’Brien Starts Oscars by Roasting Timothée Chalamet’s Ballet and Opera Controversy as Camera Cuts to ‘Marty Supreme’ Star Laughing
• TIER IV unveils AI-based Level 4 autonomous driving, accelerating global platform expansion across Japan, U.S. and Europe